scispace - formally typeset
A

Andrea M. Collins

Researcher at Liverpool School of Tropical Medicine

Publications -  73
Citations -  7924

Andrea M. Collins is an academic researcher from Liverpool School of Tropical Medicine. The author has contributed to research in topics: Medicine & Streptococcus pneumoniae. The author has an hindex of 19, co-authored 61 publications receiving 3828 citations. Previous affiliations of Andrea M. Collins include National Institute for Health Research & Aintree University Hospitals NHS Foundation Trust.

Papers
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Genetic mechanisms of critical illness in Covid-19.

Erola Pairo-Castineira, +1449 more
- 04 Mar 2021 - 
TL;DR: The GenOMICC (Genetics Of Mortality In Critical Care) genome-wide association study in 2244 critically ill Covid-19 patients from 208 UK intensive care units is reported, finding evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease.
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Katherine R. W. Emary, +69 more
- 10 Apr 2021 - 
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
Journal ArticleDOI

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.

Xinxue Liu, +90 more
- 04 Sep 2021 - 
TL;DR: The Com-COV trial as discussed by the authors evaluated vaccine safety, reactogenicity, and immunogenicity of the BNT/ChAd schedule with a 28-day or 84-day prime-boost interval.